Deep Analysis
Long-form research and cross-asset strategy.
Premium tier-1 desk read on Deep Analysis.
Free preview, full briefing via Sales.
🔓 Expert View — Research Pack
20-page quarterly cross-asset strategy report, sector deep-dives, thematic baskets. Contact sales to unlock.
Contact Sales to UnlockLatest Research
Editor-curated in-depth pieces from our 120+ archive. Tagged by region and theme.
Themes
- AI infrastructure compute build-out
- GCC sovereign capital deployment
- Asia semi cycle phase reading
- Energy transition vs petrostate cashflow
Latest in Deep Analysis
30 stories
Why Intel Stock Bounced Back Today
Here are three rumors -- and three reasons for Intel stock to be up today.…
Household worries over finances hit highest level since July 2022, New York Fed survey shows
While the central bank's monthly survey showed the inflation outlook mostly unchanged, the general perception of conditions deteriorated.…
Lululemon Shares Dropped After the Company Cut Its Annual Forecast. Is the Stock a Buy Amid the Selloff?
Lululemon stock is down 43% so far this year.…
The hiring recession is over — but landing a new job is much harder than it looks
The May jobs report blew past forecasts. Why is it taking six months to find a new job?…
Why Advanced Micro Devices Stock Bounced Back Today
AMD is making a smart investment in the U.K.…
JPMorgan traders are getting worried and have turned cautious on the market. Here's why
The recent selling in tech and volatility in the bond market have traders positioned more defensively, for now.…
Why Did IonQ Stock Bounce Back Today?
IonQ is in no immediate danger from high interest rates.…
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug.…
Here's Why the Direxion Daily Semiconductor Bull 3X ETF Soared Today (Hint: It's Alphabet and Intel Related)
The bull-and-bear debate over AI and semiconductor spending continues, with the bulls coming out on top today, backed by some big news.…
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.…
Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why
"I think the majority view is that Lilly is pulling away, kind of Secretariat-like," Jim Cramer said Monday.…
Why Ford Motor Stock Zoomed 44% in May But Has Hit the Brakes Since
Ford has made a big AI pivot, but is the stock a buy now?…
Silicon Valley’s new buyout playbook is hitting Wall Street
Instead of selling AI tools to companies, venture firms are buying legacy companies outright and rebuilding them around AI from the inside.…
Why Plug Power Stock Surged 26% in May But Is Falling Apart Again
The volatility in the hydrogen stock can be unnerving. Here's what you should do.…
Here's Why Shares in Brady Slumped Today
The market appears unduly concerned about a CEO transition, particularly given the new CEO's extensive experience.…
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.…
Apple shares reverse lower after big Siri news. Why we're not bothered
Apple delivered on what Wall Street was expecting: a complete artificial intelligence overhaul.…
Why is this Wealth Manager Buying 1 Million Shares of Harley Davidson?
Harley-Davidson generates revenue from motorcycle sales and financial services, supported by a global dealer network and iconic brand.…
Why Investors Bailed on Beyond Meat Last Month
It posted a double-digit decline in net revenue in its first quarter.…
CNBC Points Pro: How do I choose a travel credit card for maximum value?
Points expert Jason Stauffer explains how to figure out which travel credit card is the best fit for you.…
Why Chewy Stock Got Mashed in May
The company's CEO sounded a cautious note about consumers at an industry conference that month.…
Apple partnering with Google and Nvidia for most advanced AI model
Apple's artificial intelligence strategy took center stage at its Worldwide Developers Conference in Cupertino, Calif.…
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?
Infectious disease could fuel Eli Lilly's next growth phase.…
How to Pay Off a Personal Loan Faster
Rounding up monthly payments and making extra one-time payments can help you pay off a personal loan faster — but make sure it’s the best use of your funds.…
Jim Cramer warns key pillars of the bull market are beginning to crumble
CNBC's Jim Cramer said that he's becoming more cautious on stocks after several pillars of his bullish outlook have come under pressure.…
Why Motorcar Parts of America Surged Nearly 35% Higher Today
It blew past analyst estimates in its final quarter of fiscal 2026.…
Why VOO Makes More Sense as a 20-Year Hold Than a 2-Year Trade, Even at Today's Valuations
The stock market is trading at historically expensive levels. That doesn't mean long-term investors should shy away from the S&P 500.…
Star Princess Cruise in Alaska: The Views Steal the Show
Princess Cruises' newest ship shines on Alaska sailings. Our review covers cabins, dining, the Princess Premier package and whether Star Princess is worth it.…
Why Ciena Stock Stumbled Today
It's floating a large-scale convertible notes issue.…
CrowdStrike Beat Earnings, Raised Guidance, and Announced a 4-for-1 Stock Split. So, Why Did the Stock Fall?
A strong quarter and its first stock split as a public company weren't enough to satisfy a stock priced for perfection.…